B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of long-lived CD5+ B lymphocytes. TPA (12-O-tetradecanoylphorbol 13- acetate) and interleukin-4 (IL-4) inhibit apoptosis of B-CLL lymphocytes ex vivo. We used specific inhibitors of protein kinase C (PKC), extracellular-regulated kinase (ERK), and phosphatidylinositol 3–kinase (PI3-kinase) to study their involvement in TPA- and IL-4–induced survival of B-CLL lymphocytes. BisI, a specific inhibitor of PKC, induced apoptosis and inhibited the antiapoptotic activity of TPA and IL-4. B-CLL cells have a basal PKC activity that was increased by TPA but not by IL-4. TPA, but not IL-4, induced ERK activation. However, the inhibition of ERK activation did not affect the viability of B-CLL lymphocytes, demonstrating that this pathway is not involved in their survival. Inhibition of PI3-kinase by LY294002 induced apoptosis of B-CLL cells and inhibited the survival effect of IL-4 and TPA. In addition, Akt, a downstream effector of PI3-kinase activity, was phosphorylated by TPA and IL-4 in B-CLL cells, though PI3-kinase had no effect on PKC-dependent phosphorylation of Akt. Furthermore, the inhibition of PKC or PI3-kinase increased dexamethasone- and fludarabine-induced apoptosis ex vivo in the presence of survival factors. These results demonstrate that PKC and PI3-kinase are involved in the survival of B-CLL cells and suggest that inhibitors of these pathways could be combined with the drugs used in the treatment of B-CLL.

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of monoclonal CD5+ B lymphocytes.1,2 Most circulating cells appear to be nondividing, and the clonal excess of B cells results from decreased apoptosis rather than increased proliferation.3 

Apoptosis of B-CLL lymphocytes is regulated by several cytokines.4 When B-CLL lymphocytes are placed in culture medium, they undergo apoptosis,5 probably triggered by the absence of survival factor(s) that are present in vivo. Candidate survival factors that prevent apoptosis of B-CLL lymphocytes ex vivo include interleukin-4 (IL-4),6,7 interferon γ (IFN-γ),8 IFN-α,9 IL-2,10IL-6,11 IL-8,12 IL-13,13 and stromal cell–derived factor 1 (SDF-1).14 Interestingly, increased serum levels of IFN-γ8 and IL-815and increased production of IL-4 by T cells16 have been described in B-CLL. IL-4 is the most studied interleukin in preventing apoptosis of B-CLL lymphocytes ex vivo. Thus, in addition to its effects on spontaneous apoptosis, IL-4 inhibits apoptosis induced by glucocorticoids,6,17 IL-5,18IL-10,19 chlorambucil,20 and fludarabine.21 

Protein kinase pathways involved in the survival of several cell types include protein kinase C (PKC), extracellular-regulated kinase (ERK), and phosphatidylinositol 3–kinase (PI3-kinase) pathways.22-24 The phorbol ester TPA (12-O-tetradecanoylphorbol 13-acetate) and bryostatin, 2 structurally unrelated activators of PKC, have been described as inhibitors of spontaneous and chemotherapy-induced apoptosis in B-CLL lymphocytes.17,25-29 Activation of PKC triggers the ERK pathway,30,31 and IL-4 induces PI3-kinase in various cell types, including B lymphocytes.32 

PI3-kinase is an important mediator of survival factors, protecting many cell types from multiple apoptosis-inducing stimuli.23,33 PI3-kinase phosphorylates the D-3 position of phosphatidylinositol, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-diphosphate. Kinases such as 3-phosphoinositide–dependent kinase 1 (PDK1) and Akt bind to these phosphorylated intermediates through their pleckstrin homology domain. PDK1, in turn, phosphorylates and activates Akt, which has an important role in cell survival.23 

The role of PKC, ERK, and PI3-kinase pathways in the control of the apoptosis of B-CLL lymphocytes has not been reported. Here we used specific inhibitors of these kinases to study their involvement in TPA- and IL-4–induced survival of B-CLL lymphocytes. Our results indicate that PKC and PI3-kinase pathways regulate survival in B-CLL cells.

Patients

Twelve patients (7 men, 5 women) who ranged in age from 48 to 89 years (median age, 76 years) and who had not received treatment were studied. B-CLL was diagnosed according to standard clinical and laboratory criteria. Written informed consent was obtained from all patients according to the Declaration of Helsinki, and approval was obtained from the Comité de Bioètica of the Universitat de Barcelona for these studies.

Cytokines and chemical reagents

TPA, phenylmethylsulfonyl fluoride (PMSF), and propidium iodide (PI) were from Sigma Chemical (St Louis, MO). Dexamethasone was from Merck KGaA (Darmstadt, Germany). Fludarabine was from Schering AG (Berlin, Germany). Recombinant human IL-4 was from R&D Systems (Minneapolis, MN). Bisindolylmaleimide I (BisI), U0126, and LY294002 were from Calbiochem-Novabiochem (San Diego, CA).

Isolation of B-CLL cells

Peripheral blood lymphocytes from patients with B-CLL were obtained from the Hematopathology Unit at the Hospital Clinic, Barcelona, Spain. Mononuclear cells from heparinized peripheral blood were isolated by centrifugation on a Ficoll-Hypaque (Seromed, Berlin, Germany) gradient and cryopreserved in liquid nitrogen in the presence of 10% dimethyl sulfoxide.

The purity of B-CLL samples was evaluated by flow cytometry. Briefly, 5 × 105 cells were washed in phosphate-buffered saline (PBS) and were incubated in 50 μL PBS with allophycocyanin (APC)–conjugated anti-CD3 and phycoerythrin (PE)–conjugated anti-CD19 (PharMingen, Becton Dickinson, Mountain View, CA) for 10 minutes in the dark. Cells were then diluted with PBS to a volume of 250 μL and analyzed with a FACSCalibur (Becton Dickinson). Data analysis was performed with CellQuest software (Becton Dickinson). To analyze sufficient numbers of cells, a live-gate in forward scatter versus CD3 was drawn, and at least 5 × 103 CD3+ cells were acquired. The percentage of CD3+ T cells in B-CLL samples ranged from 0.4% to 5% (mean, 2.2% ± 1.5%).

Cell culture

B-CLL lymphocytes were cultured immediately after thawing at a concentration of 0.5 to 5 × 106 cells/mL in RPMI 1640 culture medium supplemented with 2 mM glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin (Biological Industries, Kibbutz Beit Haemek, Israel), and 10% heat-inactivated fetal bovine serum (Gibco BRL, Paisley, Scotland) at 37°C in a humidified atmosphere containing 5% carbon dioxide.17 The viability of B-CLL cells before commencing the incubation ranged from 62% to 91% (mean, 77% ± 9%). Factors were added 2 hours after the beginning of the culture, and cells were incubated for the indicated periods of time.

Flow cytometry analysis of phosphatidylserine exposure and cell membrane permeability

Cell viability and the rate of apoptosis were determined simultaneously by double staining with fluorescein isothiocyanate (FITC)–conjugated annexin V (Bender MedSystem, Vienna, Austria) and PI, as described previously.34 Briefly, 2 × 105 B-CLL cells were washed in PBS and resuspended in 100 μL annexin V–binding buffer (10 mM HEPES, pH 7.4, 2.5 mM CaCl2, 140 mM NaCl) containing 0.2 μL (1 μg/mL) FITC–annexin V. After 15 minutes of incubation in the dark at room temperature, cells were diluted with 100 μL annexin V–binding buffer containing 1 μg/mL PI and were analyzed with a FACSCalibur (Becton Dickinson). Data analysis was performed with CellQuest software (Becton Dickinson). Cell viability was measured as the percentage of annexin V– and PI-negative cells.

Protein kinase C activity

Protein kinase C activity was analyzed in particulate fraction containing membrane-associated PKC, as previously described,35 with minor modifications. Briefly, B-CLL cell pellets were homogenized in 200 μL of 25 mM Tris-HCl, containing 4 mM EGTA, 2 mM EDTA, 5 mM dithiothreitol, 1 mM PMSF, 1 μg/mL pepstatin, 1 μg/mL leupeptin, 1 μg/mL aprotinin, and 1 mM benzamidine, at pH 7.5 (buffer A). After 20 minutes incubation at 4°C, B-CLL cells were homogenized by 20 strokes with a dounce homogenizer. After centrifugation at 100 000g for 1 hour at 4°C, the supernatant (representing the cytosolic fraction) was collected, and the pellet was resuspended in 150 μL buffer A supplemented with 1% Triton X-100. After incubating for 1 hour at 4°C, the suspension was centrifuged at 100 000g for 1 hour at 4°C. This second supernatant (particulate fraction) contained the membrane-associate PKC. The distribution of α-tubulin was used to estimate the purity of particulate fractions.

PKC activity was assayed in both fractions by measuring the incorporation of 32P from (γ-32P)ATP (Amersham, Buckinghamshire, United Kingdom) into a highly selective peptide substrate based on neurogranin (28-43)36 (Promega, Madison, WI) at 30°C. The assay reaction mixture contained 2 μg protein from each fraction in assay buffer containing 50 mM HEPES (pH 7.5), 0.25 mM EDTA, 0.5 mM EGTA, 0.125 mM dithiothreitol, 12.5 mM MgCl2, 100 μM ATP (specific activity, 200 cpm/pmol), 0.75 mM CaCl2, 280 μg/mL phosphatidylserine, 10 μM, TPA and 50 μM peptide substrate in a final volume of 50 μL. The reaction was stopped after 10 minutes on ice, and the sample (25 μL) was applied to Whatman P-81 paper (2 × 2 cm) (Whatman, Maidstone, United Kingdom). Papers were washed 4 times in 5% orthophosphoric acid with gentle agitation for 15 minutes. Radioactivity bound to the washed papers was determined by liquid scintillation counting. PKC activity was determined after subtracting the incorporation of 32P in the absence of CaCl2, phosphatidylserine, and TPA. Proteins were determined using the Micro BCA Protein assay reagent kit (Pierce, Rockford, IL) and with bovine serum albumin as standard.

Phosphorylation in intact cells

Phosphorylation of PKC substrates in intact cells was analyzed as previously described.37 Briefly, B-CLL cells (5 × 106 cells for each condition) were washed 3 times with RPMI 1640 medium without phosphate (Biological Industries) and resuspended at 10 × 106 cells/mL in the same medium supplemented with 32P-Orthophosphate (Amersham) (200 μCi/mL [7.4 MBq/mL]) for 5 hours at 37°C. Free phosphorus was eliminated by washing 3 times with ice-cold PBS, and the cells were then incubated for the indicated times in the presence of different factors. Cells were harvested and immediately extracted with 100 μL of 100 mM Tris-HCl, pH 6.8, 0.5% Triton X-100, 2 mM EGTA, 10 mM sodium fluoride, 1 mM PMSF, 1 μg/mL pepstatin, 1 μg/mL leupeptin, 1 μg/mL aprotinin, and 1 mM benzamidine for 20 minutes at 4°C. The extract was heated at 100°C for 10 minutes and centrifuged at 13 000 rpm for 10 minutes. The same amount of cell extract was analyzed by 7.5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). 32P-labeled proteins were detected by autoradiography.

Western blot analysis of protein phosphorylation

B-CLL lymphocytes were incubated at a density of 5 × 106 cells/mL with factors for the indicated period of time, washed in ice-cold PBS, resuspended in lysis buffer containing 50 mM Tris-HCl pH 7.5, 1% Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM EDTA, 40 mM β-glycerophosphate, 100 mM NaCl, 1 μg/mL pepstatin, 1 μg/mL leupeptin, 1 μg/mL aprotinin, 1 mM benzamidine, and 1 mM PMSF, and incubated on ice for 5 to 10 minutes. After a 1-minute vortex, cell debris was eliminated by centrifugation at 13 000 rpm for 15 minutes, supernatants were collected, and protein concentrations were determined using the Micro BCA Protein assay reagent kit (Pierce). For the detection of phosphorylated forms of ERK-1/ERK-2 (ERK) and Akt, whole lysates (50 μg) were resolved by 10% SDS-PAGE, transferred to Immobilon-P membranes (Millipore, Bedford, MA), and analyzed by Western blotting with specific antibodies against phospho-ERK (Thr202/Tyr204) and phospho-Akt (Ser473) (New England BioLabs, Beverly, MA). As a confirmation of equal loading and transfer proteins, blots were stripped and reproved with antibodies against ERK (Upstate Biotechnology, Lake Placid, NY). After binding with horseradish peroxidase–conjugated secondary antibodies, blots were visualized with the enhanced chemiluminescence detection system (Amersham).

Statistical analysis

Levels of significance between samples were assessed by analysis of variance (Fisher PLSD test).

PKC inhibition blocks the survival effect of TPA and IL-4

To study the involvement of PKC in the survival of B-CLL lymphocytes, we used Bisindolylmaleimide I (BisI), a specific inhibitor of PKC.38 Treatment of B-CLL cells with 5 μM BisI induced apoptosis in 7 of 10 patients analyzed (patients 3, 4, 6, 7, 9, 11, and 12) and inhibited the survival effect of TPA and IL-4 (Table1). The induction of apoptosis by BisI in the absence of TPA or IL-4 suggested that in most cases basal PKC activity contributed to the survival of B-CLL cells. Therefore, we measured PKC activity in B-CLL cells. As shown in Figure1A, B-CLL cells have a basal membrane-associated PKC activity that corresponds to 13% of the total PKC activity. This activity was completely blocked in the presence of 1 μM BisI, corroborating that it corresponds to PKC activity. Membrane-associated PKC was increased by TPA but not by IL-4. Furthermore, we analyzed the phosphorylation level of the 3 major PKC substrates in B-CLL cells: myristoylated alanine-rich PKC substrate (MARCKS), MARCKS-related protein (MRP), and leukocyte-specific protein 1.37 39 B-CLL cells have a basal level of phosphorylation of these substrates that was inhibited by BisI, increased by TPA, and not affected by IL-4 (Figure 1B).

Fig. 1.

Analysis of PKC activity in B-CLL cells.

(A) Membrane-associated PKC activity in particulate fraction. B-CLL cells were incubated for 10 minutes in the presence of 10 nM TPA for 20 minutes in the presence of 10 ng/mL IL-4 or in medium alone. After that time, cells were harvested and lysed, and the distribution of the enzyme between cytosolic fraction and particulate fraction was evaluated. PKC activity analysis was performed as described in “Patients, materials, and methods.” The cell extract was preincubated with 1 μM BisI for 20 minutes at room temperature before reaction was initiated. Values are mean ± SD for 6 different patients. Results are shown as the percentage of PKC activity present in the particulate fraction with respect to total PKC activity (cytosolic fraction plus particulate fraction). (B) Phosphorylation of PKC substrates in intact B-CLL cells. B-CLL cells were labeled with32P as described in “Patients, materials, and methods,” in the absence or the presence of 5 μM BisI. Then cells were incubated with 10 nM TPA or 10 ng/mL IL-4 for 10 and 20 minutes, respectively. The figure shows the results corresponding to 1 representative patient from 4 patients analyzed who had similar results.

Fig. 1.

Analysis of PKC activity in B-CLL cells.

(A) Membrane-associated PKC activity in particulate fraction. B-CLL cells were incubated for 10 minutes in the presence of 10 nM TPA for 20 minutes in the presence of 10 ng/mL IL-4 or in medium alone. After that time, cells were harvested and lysed, and the distribution of the enzyme between cytosolic fraction and particulate fraction was evaluated. PKC activity analysis was performed as described in “Patients, materials, and methods.” The cell extract was preincubated with 1 μM BisI for 20 minutes at room temperature before reaction was initiated. Values are mean ± SD for 6 different patients. Results are shown as the percentage of PKC activity present in the particulate fraction with respect to total PKC activity (cytosolic fraction plus particulate fraction). (B) Phosphorylation of PKC substrates in intact B-CLL cells. B-CLL cells were labeled with32P as described in “Patients, materials, and methods,” in the absence or the presence of 5 μM BisI. Then cells were incubated with 10 nM TPA or 10 ng/mL IL-4 for 10 and 20 minutes, respectively. The figure shows the results corresponding to 1 representative patient from 4 patients analyzed who had similar results.

Close modal

Next, we analyzed the effect of BisI on the survival effect of TPA and IL-4 in combination with 2 drugs used in the chemotherapy of B-CLL: dexamethasone (DEX) and fludarabine (F). The results shown in Figure2 correspond to 3 representative patients from 10 analyzed. BisI slightly increased the dexamethasone- or fludarabine-induced apoptosis of B-CLL cells, and it inhibited the protective effect of TPA and IL-4. Taken together, these results demonstrate that PKC activity is involved in the survival of B-CLL lymphocytes.

Fig. 2.

PKC inhibition blocks the antiapoptotic effect of TPA and IL-4.

B-CLL cells from 3 representative patients were incubated for 1 hour in the presence (▪) or the absence (■) of 5 μM BisI. After that time, drugs were added to the culture, incubation continued for another 48 hours. At the end of the culture, cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Fig. 2.

PKC inhibition blocks the antiapoptotic effect of TPA and IL-4.

B-CLL cells from 3 representative patients were incubated for 1 hour in the presence (▪) or the absence (■) of 5 μM BisI. After that time, drugs were added to the culture, incubation continued for another 48 hours. At the end of the culture, cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Close modal

Analysis of ERK signaling cascades in the survival of B-CLL cells

ERK is involved in the inhibition of apoptosis in response to survival factors in various cell types.22 40 Thus, we examined the role of ERK in TPA- and IL-4–mediated survival of B-CLL cells. We first studied whether TPA and IL-4 induced the activation of ERK using specific antibodies against its phosphorylated form. ERK was phosphorylated after 15 minutes of incubation with TPA in the 7 patients analyzed (Figure 3A), and this effect was dependent on PKC activation because it was blocked by preincubation with BisI (Figure 3B). In contrast, IL-4 did not induce ERK-phosphorylation in the 7 patients analyzed. Then we analyzed the correlation between the effect of TPA on ERK phosphorylation and B-CLL survival. The dose-response for TPA-induced ERK phosphorylation showed that the phosphorylated forms of ERK were detected when cells were incubated with 10 nM TPA in the 4 patients analyzed (Figure 3C). In contrast, the protective effect of TPA on dexamethasone-induced apoptosis reached plateau levels at 1 nM (Figure 3D). Similar results were obtained on spontaneous and fludarabine-induced apoptosis (data not shown). Thus, much higher doses of TPA were needed to induce ERK phosphorylation than for survival of B-CLL cells.

Fig. 3.

TPA, but not IL-4, induces PKC-dependent phosphorylation of ERK.

Purified peripheral blood B-CLL cells from patient 1 were incubated (A) for different times with 100 nM TPA and 10 ng/mL IL-4, (B) for 20 minutes with 100 nM TPA after preincubation for 1 hour with 5 μM BisI, and (C) with different concentrations of TPA for 20 minutes. Then cells were harvested and lysed, and phosphorylated forms of ERK (P-ERK) were analyzed by Western blot. (D) Cells from patients 1 (●), 2 (■), and 3 (⧫) were incubated for 48 hours with different doses of TPA in the presence of 10 μM dexamethasone, and cell viability was determined by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Fig. 3.

TPA, but not IL-4, induces PKC-dependent phosphorylation of ERK.

Purified peripheral blood B-CLL cells from patient 1 were incubated (A) for different times with 100 nM TPA and 10 ng/mL IL-4, (B) for 20 minutes with 100 nM TPA after preincubation for 1 hour with 5 μM BisI, and (C) with different concentrations of TPA for 20 minutes. Then cells were harvested and lysed, and phosphorylated forms of ERK (P-ERK) were analyzed by Western blot. (D) Cells from patients 1 (●), 2 (■), and 3 (⧫) were incubated for 48 hours with different doses of TPA in the presence of 10 μM dexamethasone, and cell viability was determined by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Close modal

To further investigate whether the ERK cascade plays a role in TPA-induced B-CLL lymphocyte survival, we used a specific inhibitor of MEK (mitogen of extracellular regulated kinase) activation, U0126,41 42 which at a dose of 1 μM inhibited ERK activation (Figure 4A) but did not alter the survival effect of TPA (Figure 4B). Similar results were obtained using PD98059, a structurally unrelated inhibitor of ERK cascade. As expected, neither U0126 nor PD98059 inhibited IL-4–induced survival in the 7 patients analyzed (data not shown). Taken together, these results indicate that ERK is not involved in the antiapoptotic effect of TPA and IL-4 in B-CLL cells.

Fig. 4.

Inhibition of MEK/ERK-pathway did not affect the protective effect of TPA.

(A) B-CLL cells from 4 representative patients were incubated with or without 1 μM U0126 for 1 hour before the addition of 10 nM TPA for 20 minutes. ERK phosphorylation was analyzed by Western blot. (B) B-CLL cells were incubated for 1 hour in the presence (▪) or absence (■) of 1 μM U0126. After that time, drugs were added to the culture, and incubation continued for another 48 hours. At the end of the culture, cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD of 7 patients analyzed.

Fig. 4.

Inhibition of MEK/ERK-pathway did not affect the protective effect of TPA.

(A) B-CLL cells from 4 representative patients were incubated with or without 1 μM U0126 for 1 hour before the addition of 10 nM TPA for 20 minutes. ERK phosphorylation was analyzed by Western blot. (B) B-CLL cells were incubated for 1 hour in the presence (▪) or absence (■) of 1 μM U0126. After that time, drugs were added to the culture, and incubation continued for another 48 hours. At the end of the culture, cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD of 7 patients analyzed.

Close modal

PI3-kinase pathway is involved in the survival of B-CLL cells

PI3-kinase plays an important role in the suppression of apoptosis in many cell types.23 To study the role of PI3-kinase in the survival of B-CLL cells, we used LY294002, a specific inhibitor of this kinase.43 B-CLL cells from 8 patients were cultured for 48 hours with medium alone (control), TPA, or IL-4 in the presence or absence of 20 μM LY294002, a concentration that inhibits PI3-kinase,42 and the percentage of nonapoptotic cells was analyzed by flow cytometry. LY294002 triggered apoptosis in B-CLL lymphocytes in all the patients studied except for patient 8 (Table2). In most cases, the viability of cells treated with TPA or IL-4 in the presence of LY294002 was higher than that corresponding to cells incubated with LY294002 alone, but it was lower than the viability of cells incubated with TPA or IL-4, except in patient 8, in whom viability in the presence of these factors was not decreased by LY294002, and in patient 1, in whom viability in the presence of IL-4 was not affected by LY294002 (Table 2).

In addition, dose-response experiments were performed in cells from patients 1 and 3 (Figure 5). Cells were incubated with increasing concentrations of LY294002, ranging from 2 to 50 μM for 48 hours. Cell cytotoxicity was dose-dependent, and the IC50 was approximately 3 μM and 6 μM, respectively. Analysis of caspase-3 activation and PARP cleavage by Western blot showed that LY294002 activated caspase-3 in B-CLL cells (data not shown).

Fig. 5.

Dose-response effect of LY294002.

B-CLL cells from patients 1 (●) and 3 (■) were incubated with increasing doses of LY294002 for 48 hours, and cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Fig. 5.

Dose-response effect of LY294002.

B-CLL cells from patients 1 (●) and 3 (■) were incubated with increasing doses of LY294002 for 48 hours, and cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Close modal

PI3-kinase activates several downstream signal transduction pathways, including Akt and p70S6-kinase. We analyzed the involvement of these kinases on the survival of B-CLL cells. First, we studied Akt phosphorylation in B-CLL cells and whether TPA and IL-4 induced its phosphorylation. Akt phosphorylation was analyzed in samples obtained from 8 patients. In all patients, phosphorylated Akt was not detected in nonstimulated B-CLL cells. TPA (8 of 8 patients) and IL-4 (4 of 8 patients) induced Akt phosphorylation. Five representative cases are shown in Figure 6. Furthermore, the inhibition of PI3-kinase by LY294002 blocked the effect of IL-4 but did not alter the effect TPA. Rapamycin, a specific inhibitor of the activation of p70S6K, had no effect on the antiapoptotic activity of TPA or IL-4 (data not shown), indicating that p70S6K and rapamycin-dependent pathways are not involved in the survival of B-CLL cells.

Fig. 6.

Effect of TPA and IL-4 on Akt phosphorylation.

Cells from 5 representative patients were incubated with 20 μM LY294002 for 1 hour before the addition of 10 nM TPA or 10 ng/mL IL-4 to the culture. Akt phosphorylation in Ser473 was analyzed by Western blot 20 minutes after the addition of drugs.

Fig. 6.

Effect of TPA and IL-4 on Akt phosphorylation.

Cells from 5 representative patients were incubated with 20 μM LY294002 for 1 hour before the addition of 10 nM TPA or 10 ng/mL IL-4 to the culture. Akt phosphorylation in Ser473 was analyzed by Western blot 20 minutes after the addition of drugs.

Close modal

Next, we analyzed the effect of PI3-kinase inhibition on chemotherapy-induced apoptosis of B-CLL cells. LY294002 had an additive effect on the apoptotic activity of fludarabine in 3 of the 4 patients analyzed (Figure 7). However, the inhibition of PI3-kinase had no effect on dexamethasone-induced apoptosis (8 of 8 patients analyzed; data not shown). LY294002 also reduced the viability of cells treated with dexamethasone or fludarabine, in the presence of TPA or IL-4, except in patient 9, in whom TPA blocked the apoptosis induced by LY294002 (Figure 7). The effect of LY294002 was more pronounced for IL-4–induced survival than for the antiapoptotic effect of TPA in most of the patients analyzed.

Fig. 7.

Effect of LY294002 on TPA- and IL-4–induced survival on B-CLL lymphocytes.

B-CLL lymphocytes from 3 representative patients were preincubated in the presence (▪) or absence (■) of 20 μM LY294002 for 1 hour before the addition of drugs. After 48 hours of cell culture, cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Fig. 7.

Effect of LY294002 on TPA- and IL-4–induced survival on B-CLL lymphocytes.

B-CLL lymphocytes from 3 representative patients were preincubated in the presence (▪) or absence (■) of 20 μM LY294002 for 1 hour before the addition of drugs. After 48 hours of cell culture, cell viability was analyzed by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.

Close modal

We examined the signal transduction pathways involved in the survival of B-CLL cells. Two of the most studied survival factors for B-CLL cells are TPA17,21,25-29 and IL-4.6,7,13 17-19 We used specific inhibitors of kinases involved in the control of apoptosis to analyze their role in the survival of B-CLL cells.

The PKC inhibitor BisI induced apoptosis in B-CLL cells. It has been reported that UCN-01, another PKC inhibitor, induces apoptosis in these cells.44 These findings are consistent with the observation that B-CLL cells have a basal level of PKC activity. In addition, the survival activity of TPA depends on PKC activity because BisI inhibits its antiapoptotic effect. Although IL-4 did not activate PKC, BisI inhibited its survival effect, indicating that the basal PKC activity present in B-CLL cells is necessary for the protective effect of IL-4. The downstream elements of PKC-mediated survival pathway in B-CLL cells may involve activation of the transcription factor NF-κB45 and increased expression of the antiapoptotic genes Bcl-XL, Mcl-1, andXIAP.29 

TPA, but not IL-4, activated ERK in B-CLL cells. This activation was mediated by PKC, because it was completely blocked by BisI. However, the inhibition of ERK did not affect the survival effect of TPA. The activation of this protein kinase may have other roles in B-CLL lymphocytes. For instance, it may be involved in TPA-induced differentiation.46 The inability of IL-4 to induce ERK activation has been reported in other hematopoietic cells, and it could be attributed to the fact that IL-4 does not activate the Ras pathway in these cells.47 

Interestingly, the PI3-kinase–specific inhibitor LY294002 induced apoptosis in B-CLL cells. In agreement with these results B-CLL cells have basal PI3-kinase activity (manuscript in preparation). Furthermore, the apoptotic effect of LY294002 was not completely prevented by IL-4 and TPA in many patients with B-CLL. PI3-kinase activity is important in IL-4–induced survival, which was almost blocked by LY294002 in most of the patients analyzed. Our results indicate that PI3-kinase is an important survival pathway for B-CLL cells, and they are consistent with the finding that peritoneal CD5+ B cells from mice with targeted disruption of p85α, a regulatory subunit of PI3-kinase, show decreased survival after incubation with IL-4.48,49 Several cytokines that induce survival of B-CLL cells, including IL-4, IL-2, tumor necrosis factor-α, IL-6, and IL-13, induce the activation of PI3-kinase in B lymphocytes and other cell types.50-53 Thus, the PI3-kinase pathway could contribute to the survival mediated by these cytokines in B-CLL cells. The antiapoptotic effect of TPA was not impaired in some cases by LY294002, suggesting that PKC may act in a parallel pathway or may be a downstream effector of PI3-kinase, as described in other cells.54 

One downstream effector of PI3-kinase is Akt/PKB, which is a major participant in cell survival.23 Akt phosphorylates and inactivates at least 2 proteins involved directly in the control of apoptosis, Bad55,56 and Caspase-9.57 Bad is not expressed in most B-CLL samples,58 and the phosphorylation of caspase-9 has not been analyzed in B-CLL cells. In addition to inactivating apoptosis-regulating proteins, Akt may control the expression of genes involved in cell survival. Thus, Akt phosphorylates 3 members of the Forkhead family of transcription factors,23 which are retained in the cytoplasm, thus impairing the transcription of proapoptotic genes such asFasL59 and Bim.60 We found that TPA and IL-4 induce phosphorylation of Akt in B-CLL cells. Although TPA induced Akt phosphorylation, this effect was independent of PI3-kinase. This suggests that PI3-kinase–dependent activation of Akt does not contribute to PKC-induced survival in B-CLL cells. Thus, we propose that the effect of LY294002 in basal conditions or in cells stimulated with TPA was caused by the inhibition of PI3-kinase and a downstream PI3-kinase–dependent signaling pathway but that it was likely independent of Akt activity. However, we cannot rule out the involvement of Akt in TPA-induced B-CLL cell survival. IL-4 induced Akt phosphorylation in 50% of the cases analyzed, and this phosphorylation depends on PI3-kinase, suggesting that this is one of the mechanisms by which the activation of PI3-kinase induces survival of these cells, as described in many other systems.23 In addition, several protein kinases downstream of PI3-kinase involved in cell survival have been described, including several isotypes of PKC54 and CISK/SGK3.61 The role of these pathways in the survival of B-CLL cells will be analyzed in the future.

In conclusion, our results demonstrate that PI3-kinase and PKC play important roles in the survival of B-CLL cells. Because inhibition of these kinases increases chemotherapy-induced apoptosis ex vivo in the presence of survival factors, this finding could contribute to the design of new therapeutic strategies. For example, combinations of drugs used in the treatment of B-CLL with inhibitors of PKC or PI3-kinase should be considered. Finally, the elucidation of the downstream components of the PI3-kinase and PKC pathways in the survival of B-CLL cells may suggest new pharmacologic targets for B-CLL therapy.

We thank Dra M. Dalmau for technical support in flow cytometry analysis. We also thank Dra E. Castaño, Dra M. Piqué, Dr F. Vinyals, Dr J. M. López-Blanco, D. Iglesias, and Dra N. Villamor for comments, helpful discussions, and suggestions, and R. Rycroft for language assistance.

Supported by grants from the Ministerio de Ciencia y Tecnologı́a (SAF 98-0100 and SAF2001-3026) (J.G.). M.B., B.B., and C.C. are recipients of a research fellowship from the Ministerio de Ciencia y Tecnologı́a, the Instituto de Salud Carlos III, and the Fundación Ramón Areces, respectively.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Kipps
TJ
Chronic lymphocytic leukemia.
Curr Opin Hematol.
5
1998
244
253
2
Keating
MJ
Chronic lymphocytic leukemia.
Semin Oncol.
26
1999
107
114
3
Reed
JC
Molecular biology of chronic lymphocytic leukemia.
Semin Oncol.
25
1998
11
18
4
Jurlander
J
The cellular biology of B-cell chronic lymphocytic leukemia.
Crit Rev Oncol Hematol.
27
1998
29
52
5
Collins
RJ
Verschuer
LA
Harmon
BV
Prentice
RL
Pope
JH
Kerr
JF
Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro.
Br J Haematol.
71
1989
343
350
6
Dancescu
M
Rubio-Trujillo
M
Biron
G
Bron
D
Delespesse
G
Sarfati
M
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.
J Exp Med.
176
1992
1319
1326
7
Panayiotidis
P
Ganeshaguru
K
Jabbar
SA
Hoffbrand
AV
Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro.
Br J Haematol.
85
1993
439
445
8
Buschle
M
Campana
D
Carding
SR
Richard
C
Hoffbrand
AV
Brenner
MK
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.
J Exp Med.
177
1993
213
218
9
Panayiotidis
P
Ganeshaguru
K
Jabbar
SA
Hoffbrand
AV
Alpha-interferon (alpha-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro.
Br J Haematol.
86
1994
169
173
10
Huang
RW
Tsuda
H
Takatsuki
K
Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells.
Int J Hematol.
58
1993
83
92
11
Reittie
JE
Yong
KL
Panayiotidis
P
Hoffbrand
AV
Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia.
Leuk Lymphoma.
22
1996
83
90
12
Francia di Celle
P
Mariani
S
Riera
L
Stacchini
A
Reato
G
Foa
R
Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.
Blood.
87
1996
4382
4389
13
Chaouchi
N
Wallon
C
Goujard
C
et al
Interleukin-13 inhibits interleukin-2–induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis.
Blood.
87
1996
1022
1029
14
Burger
JA
Tsukada
N
Burger
M
Zvaifler
NJ
Dell'Aquila
M
Kipps
TJ
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
Blood.
96
2000
2655
2663
15
Francia di Celle
P
Carbone
A
Marchis
D
et al
Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein.
Blood.
84
1994
220
228
16
Mainou-Fowler
T
Miller
S
Proctor
SJ
Dickinson
AM
The levels of TNFα, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL).
Leuk Res.
25
2001
157
163
17
Bellosillo
B
Dalmau
M
Colomer
D
Gil
J
Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells.
Blood.
89
1997
3378
3384
18
Mainou-Fowler
T
Craig
VA
Copplestone
JA
Hamon
MD
Prentice
AG
Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4.
Blood.
84
1994
2297
2304
19
Fluckiger
AC
Durand
I
Banchereau
J
Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells.
J Exp Med.
179
1994
91
99
20
Mentz
F
Mossalayi
MD
Ouaaz
F
et al
Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells.
Blood.
88
1996
2172
2182
21
Byrd
JC
Shinn
C
Waselenko
JK
et al
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Blood.
92
1998
3804
3816
22
Cross
TG
Scheel-Toellner
D
Henriquez
NV
Deacon
E
Salmon
M
Lord
JM
Serine/threonine protein kinases and apoptosis.
Exp Cell Res.
256
2000
34
41
23
Datta
SR
Brunet
A
Greenberg
ME
Cellular survival: a play in three Akts.
Genes Dev.
13
1999
2905
2927
24
O'Gorman
DM
Cotter
TG
Molecular signals in anti-apoptotic survival pathways.
Leukemia.
15
2001
21
34
25
O'Connor
TW
Phorbol ester-induced loss of colchicine ultrasensitivity in chronic lymphocytic leukaemia lymphocytes.
Leuk Res.
9
1985
885
895
26
McConkey
DJ
Aguilar-Santelises
M
Hartzell
P
et al
Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells.
J Immunol.
146
1991
1072
1076
27
Forbes
IJ
Zalewski
PD
Giannakis
C
Cowled
PA
Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester.
Exp Cell Res.
198
1992
367
372
28
Robertson
LE
Chubb
S
Meyn
RE
et al
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Blood.
81
1993
143
150
29
Kitada
S
Zapata
JM
Andreeff
M
Reed
JC
Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
Br J Haematol.
106
1999
995
1004
30
Kolch
W
Heidecker
G
Kochs
G
et al
Protein kinase C alpha activates RAF-1 by direct phosphorylation.
Nature.
364
1993
249
252
31
Schönwasser
DC
Marais
RM
Marshall
CJ
Parker
PJ
Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes.
Mol Cell Biol.
18
1998
790
798
32
Nelms
K
Keegan
AD
Zamorano
J
Ryan
JJ
Paul
WE
The IL-4 receptor: signaling mechanisms and biologic functions.
Annu Rev Immunol.
17
1999
701
738
33
Yao
R
Cooper
GM
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.
Science.
267
1995
2003
2006
34
Bellosillo
B
Piqué
M
Barragán
M
et al
Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells.
Blood.
92
1998
1406
1414
35
Colomer
D
Vives-Corrons
JLL
Bartrons
R
Effect of TPA on fructose 2,6-bisphosphate levels and protein kinase C activity in B-chronic lymphocytic leukemia (B-CLL).
Biochim Biophys Acta.
1097
1991
270
274
36
Chen
SJ
Klann
E
Gower
MC
Powell
CM
Sessoms
JS
Sweatt
JD
Studies with synthetic peptide substrates derived from the neuronal protein neurogranin reveal structural determinants of potency and selectivity for protein kinase C.
Biochemistry.
32
1993
1032
1039
37
Carballo
E
Colomer
D
Vives
CJ
Blackshear
PJ
Gil
J
Phosphorylation of the MARCKS family of protein kinase C substrates in human B chronic lymphocytic leukemia cells.
Leukemia.
9
1995
834
839
38
Toullec
D
Pianetti
P
Coste
H
et al
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
J Biol Chem.
266
1991
15771
15781
39
Carballo
E
Colomer
D
Vives-Corrons
JL
Blackshear
PJ
Gil
J
Characterization and purification of a protein kinase C substrate in human B cells: identification as lymphocyte-specific protein 1 (LSP1).
J Immunol.
156
1996
1709
1713
40
Xia
Z
Dickens
M
Raingeaud
J
Davis
RJ
Greenberg
ME
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
Science.
270
1995
1326
1331
41
Favata
MF
Horiuchi
KY
Manos
EJ
et al
Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
J Biol Chem.
273
1998
18623
18632
42
Davies
SP
Reddy
H
Caivano
M
Cohen
P
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Biochem J.
351
2000
95
105
43
Vlahos
CJ
Matter
WF
Hui
KY
Brown
RF
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
J Biol Chem.
269
1994
5241
5248
44
Kitada
S
Zapata
JM
Andreeff
M
Reed
JC
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
Blood.
96
2000
393
397
45
Furman
RR
Asgary
Z
Mascarenhas
JO
Liou
HC
Schattner
EJ
Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
J Immunol.
164
2000
2200
2206
46
Tötterman
TH
Nilsson
K
Sundström
C
Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells.
Nature.
288
1980
176
178
47
Ueno
H
Sasaki
K
Honda
H
et al
c-Cbl is tyrosine-phosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinositol 3'-kinase pathway.
Blood.
91
1998
46
53
48
Suzuki
H
Terauchi
Y
Fujiwara
M
et al
Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase.
Science.
283
1999
390
392
49
Fruman
DA
Snapper
SB
Yballe
CM
et al
Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α.
Science.
283
1999
393
397
50
Ahmed
NN
Grimes
HL
Bellacosa
A
Chan
TO
Tsichlis
PN
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.
Proc Natl Acad Sci U S A.
94
1997
3627
3632
51
Ozes
ON
Mayo
LD
Gustin
JA
Pfeffer
SR
Pfeffer
LM
Donner
DB
NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase.
Nature.
401
1999
82
85
52
Wright
K
Kolios
G
Westwick
J
Ward
SG
Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation: evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism.
J Biol Chem.
274
1999
17193
17201
53
Chen
RH
Chang
MC
Su
YH
Tsai
YT
Kuo
ML
Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways.
J Biol Chem.
274
1999
23013
23019
54
Le Good
JA
Ziegler
WH
Parekh
DB
Alessi
DR
Cohen
P
Parker
PJ
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1.
Science.
281
1998
2042
2045
55
del Peso
L
González-Garcı́a
M
Page
C
Herrera
R
Nuñez
G
Interleukin-3–induced phosphorylation of BAD through the protein kinase Akt.
Science.
278
1997
687
689
56
Datta
SR
Dudek
H
Tao
X
et al
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
Cell.
91
1997
231
241
57
Cardone
MH
Roy
N
Stennicke
HR
et al
Regulation of cell death protease caspase-9 by phosphorylation.
Science.
282
1998
1318
1321
58
Kitada
S
Andersen
J
Akar
S
et al
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses.
Blood.
91
1998
3379
3389
59
Brunet
A
Bonni
A
Zigmond
MJ
et al
Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor.
Cell.
96
1999
857
868
60
Dijkers
PF
Medemadagger
RH
Lammers
JW
Koenderman
L
Coffer
PJ
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1.
Curr Biol.
10
2000
1201
1204
61
Liu
D
Yang
X
Songyang
Z
Identification of CISK, a new member of the SGK kinase family that promotes IL-3–dependent survival.
Curr Biol.
10
2000
1233
1236

Author notes

Joan Gil, Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, c/Feixa Llarga s/n, E-08907 L'Hospitalet de Llobregat, Spain; e-mail:joangil@bellvitge.bvg.ub.es.

Sign in via your Institution